June 2025, 6 (Thursday) The National Defense Academy of Japan, Institute for Advanced Science and Technology, Global Security Center (https://www.nda.ac.jp/cc/gs/) The 1st Colloquium of FYXNUMX^{* 1}At the event, Masahiro Morimoto, Representative Director and President/CEO of the Board of Directors, gave a speech on the subject of "Economic Security as Seen through the Domestic AI KIBIT."

The summit aims to identify issues Japan currently faces in terms of systems, funding, human resource development, and research and development, and to invite a wide range of stakeholders involved in drug discovery, including industry, government, academia, and the private sector, to actively discuss measures to resolve these issues in order to build a drug discovery ecosystem that will lead to stronger drug discovery capabilities. The summit aims to widely disseminate the content of these discussions and the resulting measures to society, leading to the revitalization of drug discovery innovation originating in Japan.

The lecture will focus on the use of FRONTEO's proprietary specialized AI "KIBIT" to improve economic security.^{* 2}supply chain analysis and shareholder control network analysis in the field, and drug target discovery in the field of drug discovery support^{* 3}and its hypothesis generation^{* 4}He introduced visualization examples related to the following:

More than 50 participants gathered, and they commented that "The KIBIT use cases were very interesting and provided many insights."

Through research and development and social implementation of innovative AI technologies, solutions, and services, FRONTEO will contribute to economic security measures for companies and countries, support drug discovery, and strive to solve important social issues.

*1 Colloquium: A research presentation and lecture event on an academic topic hosted by the Global Security Center of the National Defense Academy of Japan's Institute for Advanced Science and Technology.
*2 Economic security: Ensuring economic prosperity and safety through economic measures. For companies, this includes strengthening and risk management of supply chains, due diligence regarding human rights and investment and business partners, compliance with domestic and international laws and regulations, and prevention of technology and information leaks.
*3 Target discovery: The process of identifying molecules (genes) on which a drug acts. Selecting targets whose functions can be suppressed or activated by a drug to treat a disease or alleviate symptoms.
*4 Hypothesis generation: Visualizing the mechanism of a disease and the reasons why targeting the presented molecules is thought to be effective in treating the disease, and explaining them with evidence.

About FRONTEO's economic security AI solution "KIBIT Seizu Analysis"
　https://osint.fronteo.com/
KIBIT Seizu Analysis is a system equipped with FRONTEO's proprietary analytical technology that performs network analysis of supply chains and the control status of companies by their actual shareholders for the purpose of economic security measures. Currently, we offer the following three solutions.

1) Supply chain analysis solution: Identify choke points (strategically important points) in the supply chain, possible connections with groups of concern, and the degree of dependency
② Shareholder control network analysis solution: Analyzes the influence between shareholders in a complex network using a unique method that adjusts for indirect shareholding ratios, and identifies the propagation of hidden control.
3) Researcher network analysis solution: Analyzes the personal connections of researchers in research and development related to sensitive technologies, focusing on the organizations to which the researchers belong, and identifies the risks based on that.

About FRONTEO's AI drug discovery support service "Drug Discovery AI Factory (DDAIF)"
　https://lifescience.fronteo.com/products/drug-discovery-ai-factory/
"FRONTEO Drug Discovery AI Factory (DDAIF)" is an AI drug discovery support service that combines the knowledge of FRONTEO's drug discovery researchers and AI engineers with "KIBIT" (patented in Japan and the US), an AI specialized in natural language processing. It strongly supports researchers' decision-making in drug development by analyzing disease-related gene networks and building hypotheses about target candidates.
This service has already been introduced at several major pharmaceutical companies and is accumulating a proven track record.

[Co-creation project with pharmaceutical companies]
-FRONTEO and Chugai Pharmaceutical Launch Co-Creation Project for Target Discovery Using Drug Discovery AI Factory
-EA Pharma and FRONTEO launch co-creation project to explore drug discovery targets using AI
-FRONTEO and Eisai Launch Co-Creation Project for Target Discovery Using Drug Discovery AI Factory
-FRONTEO and Maruishi Pharmaceutical Launch Co-Creation Project for Biomarker Discovery Using Drug Discovery AI Factory
-FRONTEO and UBE launch co-creation project on drug repositioning using Drug Discovery AI Factory
[Joint research projects with academia]
-FRONTEO and Tokyo University of Science begin joint research to identify new drug discovery targets using the "Drug Discovery AI Factory"
-FRONTEO and Kumamoto University begin joint research to discover new cancer treatments using Drug Discovery AI Factory